Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs.
Several growth factors (or cytokines) have been recently investigated for their use as potential therapeutics for periodontal tissue regeneration. The objective of this study was to evaluate periodontal tissue regeneration, including new bone and cementum formation, following topical application of recombinant basic fibroblast growth factor (bFGF, FGF-2) to furcation class II defects. Twelve furcation class II bone defects were surgically created in six beagle dogs, then recombinant bFGF (30 micro g/site) + gelatinous carrier was topically applied to the bony defects. Six weeks after application, periodontal regeneration was analyzed. In all sites where bFGF was applied, periodontal ligament formation with new cementum deposits and new bone formation was observed histomorphometrically, in amounts greater than in the control sites. Basic FGF-applied sites exhibited significant regeneration as represented by the new bone formation rate (NBR) (83.6 +/- 14.3%), new trabecular bone formation rate (NTBR) (44.1 +/- 9.5%), and new cementum formation rate (NCR) (97.0 +/- 7.5%). In contrast, in the carrier-only sites, the NBR, NTBR, and NCR were 35.4 +/- 8.9%, 16.6 +/- 6.2%, and 37.2 +/- 15.1%, respectively. Moreover, no instances of epithelial down growth, ankylosis, or root resorption were observed in the bFGF-applied sites examined. The present results indicate that topical application of bFGF can enhance considerable periodontal regeneration in artificially created furcation class II bone defects of beagle dogs.
Murakami
S
S
Department of Periodontology, Division of Oral Biology and Disease Control, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan. ipshinya@dent.osaka-u.ac.jp
Takayama
S
S
Kitamura
M
M
Shimabukuro
Y
Y
Yanagi
K
K
Ikezawa
K
K
Saho
T
T
Nozaki
T
T
Okada
H
H
D000539:Alveolar Process / Q000187:drug effects; D000818:Animals; D000844:Ankylosis / Q000473:pathology; D025021:Cementogenesis / Q000187:drug effects; D003739:Dental Cementum / Q000187:drug effects; D004195:Disease Models, Animal; D004285:Dogs; D004337:Drug Carriers; D004848:Epithelium / Q000473:pathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D017823:Furcation Defects / Q000145:classification / Q000188:drug therapy*; D005782:Gels; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010513:Periodontal Ligament / Q000187:drug effects; D010519:Periodontium / Q000187:drug effects*; D011994:Recombinant Proteins; D012038:Regeneration / Q000187:drug effects*; D012391:Root Resorption / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects
D004337:Drug Carriers; D005782:Gels; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2